Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20268 Citations
SS-31 (elamipretide) earned FDA accelerated approval for Barth syndrome in September 2025, targeting mitochondrial cardiolipin to restore energy production. Community users run 2 to 10 mg daily for fatigue and longevity. Injection site reactions affect nearly everyone at some point.
4mcg · Daily
Summary: Add 2mL BAC water to your 5mg vial. Draw to 0.2 units on a U-100 syringe for a 4mcg dose. This vial will last 1250 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 4mg | Daily |
| Moderate | 10mg | Daily |
| Aggressive | 40mg | Daily |
Reconstitution math first. A 10 mg vial with 1 mL bacteriostatic water gives you 10 mg/mL. At that concentration, 4 mg equals 40 units on a U-100 insulin syringe (0.4 mL). A 10 mg dose takes the full syringe (100 units, 1.0 mL). For the 40 mg vial, add 4 mL BAC water for the same 10 mg/mL concentration; 10 mg is still 100 units, but you get four doses per vial instead of one. Morning dosing is the community standard. There is no meal timing requirement. You'll want to pre-treat injection sites. Cetirizine 10 mg taken 30 minutes before your shot makes a real difference for the first few weeks. Rotate between abdomen and upper thigh, and inject slowly. The site reactions are the number one reason people quit early. Get a CBC at baseline and again at week 8. The eosinophilia is expected, but you want a record showing it was absent before you started. Store lyophilized powder at minus 20 degrees Celsius. After reconstitution, keep it at 4 degrees Celsius and use within 28 days.
Dosing based on SS-31 (elamipretide) allometric dose extrapolation from preclinical data; FDA label dose differs — 13 published references.View all sources →
Cross-check your SS-31 (Elamipretide) reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
SS-31 (elamipretide) earned FDA accelerated approval for Barth syndrome in September 2025, targeting mitochondrial cardiolipin to restore energy production. Community users run 2 to 10 mg daily for fatigue and longevity. Injection site reactions affect nearly everyone at some point.